Antares Pharma (ATRS)

Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), Covis Pharma (Covis), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd. (Idorsia). Antares Pharma's FDA-approved products include XYOSTED® (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva. The Company also markets NOCDURNA® (desmopressin acetate) in the U.S., which was licensed from Ferring Pharmaceuticals.

Company profile

Ticker

ATRS

Exchange

NASDAQ

Website

www.antarespharma.com

CEO

Robert Apple

Incorporated

Delaware

Location

New Jersey

Fiscal year end

Dec 31

Sector

Manufacturing > Surgical and Medical Instrument Manufacturing

Industry (SIC)

Surgical & Medical Instruments & Apparatus

3M • Baxter International • Boston Scientific • Stryker • Becton, Dickinson And • Teleflex • Resmed • Hill-Rom • Nuvasive • Integra Lifesciences ...

Former names

ANTARES PHARMA INC, ANTARES PHARMA INC, ANTARES PHARMA INC /MN/, MEDI JECT CORP /MN/

SEC CIK

0001016169

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

IRS number

411350192

ATRS stock data

1M 1Y 5Y

News

From Benzinga Pro

Looking Into Antares Pharma's Return On Invested Capital

8 Jun 22

Benzinga Pro data, Antares Pharma (NASDAQ:ATRS) reported Q1 sales of $41.56 million. Earnings fell to a loss of $2.32 million, resulting in a 107.1% decrease from last quarter.

Press releases

From Benzinga Pro

Hart-Scott-Rodino Waiting Period Expires for Halozyme's Acquisition of Antares Pharma

12 May 22

SAN DIEGO, May 12, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended

Calendar

10 May 22

9 Aug 22

31 Dec 22

Financial summary

Financial statements Chart ATRS financial data

Quarter (USD)	Mar 22	Dec 21	Sep 21	Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	61.72M	61.72M	61.72M	61.72M	61.72M	61.72M
Cash burn (monthly)	1.4M	(no burn)	1.05M	(no burn)	1.63M	(no burn)
Cash used (since last report)	6.02M	n/a	4.5M	n/a	7M	n/a
Cash remaining	55.69M	n/a	57.21M	n/a	54.71M	n/a
Runway (months of cash)	39.8	n/a	54.7	n/a	33.6	n/a

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Recent insider trades

ATRS insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value
24 May 22	Greenleaf Peter	Common Stock	Sale back to company	Dispose D	No	No	5.6	49,425	276.78K
24 May 22	Greenleaf Peter	Common Stock	Sale back to company	Dispose D	No	No	5.6	30,220	169.23K
24 May 22	Greenleaf Peter	Stock Option Common Stock	Sale back to company	Dispose D	No	No	4.42	48,542	214.56K
24 May 22	Greenleaf Peter	Stock Option Common Stock	Sale back to company	Dispose D	No	No	2.73	58,246	159.01K
24 May 22	Greenleaf Peter	Stock Option Common Stock	Sale back to company	Dispose D	No	No	2.92	46,729	136.45K
24 May 22	Greenleaf Peter	Stock Option Common Stock	Sale back to company	Dispose D	No	No	3.11	20,000	62.2K
24 May 22	Powell Fred M	Common Stock	Sale back to company	Dispose D	No	No	5.6	124,234	695.71K
24 May 22	Powell Fred M	Common Stock	Sale back to company	Dispose D	No	No	5.6	204,022	1.14M
24 May 22	Powell Fred M	Common Stock	Sale back to company	Dispose D	No	No	5.6	587,014	3.29M
24 May 22	Powell Fred M	Stock Option Common Stock	Sale back to company	Dispose D	No	No	4.42	163,963	724.72K

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Institutional ownership, Q1 2022

ATRS institutional ownership history Ownership history

53.6% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	175	162	+8.0%
Opened positions	25	20	+25.0%
Closed positions	12	28	-57.1%
Increased positions	56	58	-3.4%
Reduced positions	57	55	+3.6%

13F shares	Current	Prev Q	Change
Total value	375.15M	346.5M	+8.3%
Total shares	91.58M	85.61M	+7.0%
Total puts	24.8K	34.2K	-27.5%
Total calls	316.9K	80.7K	+292.7%
Total put/call ratio	0.1	0.4	-81.5%

Largest owners	Shares	Value	Change
BLK Blackrock	11.95M	$49.01M	-0.6%
Rubric Capital Management	10.9M	$44.69M	+0.9%
Vanguard	8.64M	$35.44M	+2.3%
Sargent Investment	3.66M	$15.02M	-0.9%
Amundi	3.45M	$13.95M	+38.2%
STT State Street	3.45M	$14.14M	+3.2%
Stonepine Capital Management	3.13M	$12.83M	+36.3%
Russell Investments	3.05M	$12.49M	+166.6%
Geode Capital Management	3M	$12.3M	+2.2%
First Wilshire Securities Management	2.8M	$11.48M	+1.2%

Largest transactions	Shares	Bought/sold	Change
Russell Investments	3.05M	+1.9M	+166.6%
Magnetar Financial	375.55K	-1.38M	-78.6%
Velan Capital Investment Management	1.35M	+1.35M	NEW
Amundi	3.45M	+953.45K	+38.2%
Stonepine Capital Management	3.13M	+832.83K	+36.3%
Assenagon Asset Management	1.04M	+785.44K	+311.3%
FMR	292.97K	-545.91K	-65.1%
Citadel Advisors	448.69K	+395.19K	+738.7%
Millennium Management	468.46K	+362.86K	+343.6%
Dimensional Fund Advisors	1.93M	+332.97K	+20.9%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Mylan • Agile Therapeutics • Mylan II B.V. • Viatris

Risks

We may not complete the pending transaction with Halozyme within the time frame we anticipate or at all, which could have an adverse effect on our business, financial results and/or operations.
The pendency of the transaction with Halozyme could adversely affect, or disrupt, our business, financial results and/or operations.
While the Merger Agreement is in effect, we are subject to restrictions on our business activities.
In certain instances, the Merger Agreement requires us to pay a termination fee to Halozyme, which could require us to use available cash that would have otherwise been available for general corporate purposes.
We have incurred, and will continue to incur, direct and indirect costs as a result of the pending transaction with Halozyme.

Management Discussion

Net revenue from product sales for the three months ended March 31, 2022 increased 10.2% over the same period in the prior year primarily driven by higher shipments of sumatriptan, epinephrine and teriparatide auto injectors to Teva and an increase in XYOSTED® proprietary product sales. The overall increase was partially offset by a reduction in OTREXUP® proprietary sales due to the sale of the OTREXUP® product line to Otter in December 2021.
Sales of our proprietary products XYOSTED® and NOCDURNA® (and OTREXUP® during the three months ended March 31, 2021) are presented net of estimated product returns and sales allowances. FDA approval was granted on March 28, 2022 to commercialize TLANDO® with no sales transacted in the three months ended March 31, 2022 prior to timing of the approval. The decreases in proprietary product sales of 7.8% for the three months ended March 31, 2022 was primarily attributable to a reduction in OTREXUP® proprietary sales due to the sale of the OTREXUP® product line to Otter in December 2021 which is now commercialized by Otter, partially offset by continued growth in prescriptions and sales of XYOSTED® and NOCDURNA®.
We also manufacture and sell devices, components and fully assembled and packaged product to our partners. Partnered product sales increased 42.5% for the three months ended March 31, 2022 primarily due to higher shipments of sumatriptan, epinephrine and teriparatide auto injectors to Teva.

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: absent, acquisition, Additionally, affirmative, affirming, annum, Antitrust, appraisal, Assertio, assumption, attention, bankruptcy, bear, benchmark, beneficially, Berry, book, candidate, casualty, certificate, cessation, CG, challenging, Circuit, clearance, condemnation, consent, constant, consummated, consummation, contend, covenant, create, curtail, customary, deadline, decide, defense, deficit, Delaware, Denise, deny, deposit, desire, devote, DGCL, difficult, direct, directed, directly, disorder, diversion, diverted, drawn, Eastern, EBITDA, economy, eliminated, elimination, engineering, enjoin, environment, event, exacerbated, exceed, expansion, extinguished, fact, failure, Fast, fewer, fluidity, gain, greater, Group, guaranteed, guarantor, Halozyme, harm, highest, hiring, hold, hope, HSR, hybrid, identical, iii, immunology, impossible, incurrence, independent, indirect, injunctive, installment, intent, interaction, intercompany, irrevocably, Joe, Jordan, Joseph, Lawrence, ligation, longer, macroeconomic, Matthew, member, merge, merger, minimum, modify, month, motivate, negative, negatively, notified, Ochoa, offer, omission, ordinary, organizational, Otter, par, passed, penalty, pendency, Pennsylvania, perfected, permitted, pivotal, pledge, practice, prefilled, premium, prepay, prime, proceeding, progressing, proper, properly, prospective, purportedly, qualified, rare, recover, recruit, Redfield, reinvestment, relationship, relief, repaid, repurchase, reputation, rescission, rescissory, retention, revise, Richard, Rule, ruled, sample, SEC, settlement, Shiva, slight, software, Southern, statutory, Stein, strictly, subsidiary, Supreme, surviving, syringe, team, tender, tendered, terminated, terminating, termination, thereof, thereunder, tied, timeframe, Track, trademark, TRT, turn, Undue, unused, Vai, validly, variety, vendor, viability, voluntarily, waiting, waiver, Wilson, withdrawn, withholding, York

Removed: accelerated, accurate, allocation, amortizing, Arab, Arabia, ASC, Bone, capability, collaborating, commercializing, comprised, confirmatory, conform, defend, executing, finance, fluctuate, fluctuation, Gestation, guidance, heading, inaccuracy, inaccurate, incremental, interpret, leave, Neonatal, office, opinion, Optimizing, phased, PROLONG, promote, promotion, prove, publicly, pursue, reach, recently, reclassified, recommend, released, Reproductive, Role, Saudi, sheet, structured, taxable, temporary, Topic, unanticipated, unmet, Urologic, utilization, varying, vigorously, virtually, voted, withdrawal

From filing 10-Q 2022 Q1

Financial reports

View all

Annual report (amended)

29 Apr 22

10-K